Eli Lilly and Co
Analysts predicted new obesity medicines would be blockbusters. Now they’re raising their forecasts
As new weight loss medications garnered buzz last year, analysts’ forecasts signaled these drugs would be blockbusters, with some of the highest estimates calling for peak sales of at least $100 billion. In recent days, the expectations are moving higher still. The initial projections were made before Wall Street saw the results of Novo Nordisk’s […]
Read More
Ozempic, Wegovy may curb drinking, smoking and other addictive behaviors – here’s what we know
An Ozempic (semaglutide) injection pen is seen on a kitchen table in Riga, Latvia on 06 August, 2023. Jaap Arriens | Nurphoto | Getty Images Heather Le Biller shed 9 pounds within the first week of taking Novo Nordisk‘s blockbuster diabetes drug Ozempic – and then even more as she continued treatment. Le Biller, a […]
Read More
Big pharma’s blockbuster obesity drug battle is just getting started, and it’s headed for $100 billion
Ozempic drug to treat diabetes. Courtesy: Ozempic In their most recent earnings reports, Novo Nordisk and Eli Lilly proved why they are the undisputed heavyweights in the prizefight for control of the rapidly growing weight-loss medications market. Beyond staggering sales figures for Novo’s Ozempic and Wegovy and Lilly’s Mounjaro, news of a study showing Wegovy […]
Read More
Obesity drugs’ popularity put a dent in these stocks. Why analysts say they’re still worth buying
Industry analysts are insisting that new weight loss and diabetes drugs like Ozempic won’t hurt the demand for insulin pumps and continuous glucose monitors, but most investors aren’t buying it. Medical device stocks have been falling session after session, prompting UBS analyst Danielle Antalffy on Wednesday to lower her price targets for Dexcom and a […]
Read More
Blockbuster weight loss drugs Wegovy and Ozempic are being tested to treat addiction and dementia
Weight loss drugs are being assessed for their ability to treat conditions like dementia and addiction after a landmark study showed that Wegovy helped reduce the risk of heart attacks and strokes. Bloomberg | Bloomberg | Getty Images LONDON — Scientists have begun investigating whether so-called miracle obesity drugs could be used to treat conditions […]
Read More
‘Robot pills’ could one day help patients avoid needles. The stocks are cheap, but risky
Ask most patients if they prefer to receive medicine by swallowing a pill, by injection or infusion, and most will likely opt for the pill. But that’s not always possible for drugs that use delicate molecules that can’t tolerate the physical and chemical conditions in the gastrointestinal tract. That’s where a number of early-stage drug […]
Read More
Medicare wants to cut the price on an Eli Lilly drug. What it means for LLY shares
Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.’s shares climbed in early US trading after its experimental drug for Alzheimer’s slowed the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval. AJ Mast | Bloomberg | Getty […]
Read More
Weight loss drugs boost sales at retail pharmacies, but they may not help profits much
A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. George Frey | Reuters Drugmakers aren’t the only ones feeling the impact of the weight loss industry gold rush. Retailers with pharmacy businesses, such […]
Read More
This biotech name is one of Jim Cramer’s favorite stocks and he thinks it can go even higher
Regeneron Pharmaceuticals (REGN) rose Monday after the Food and Drug Administration approved a higher-dose formulation of Eylea, the company’s macular degeneration treatment. If you like this story, sign up for Jim Cramer’s Top 10 Morning Thoughts on the Market email newsletter for free. CNBC’s Jim Cramer said on “Squawk on the Street” that Regeneron is […]
Read More
Redwire and Sierra team up to make drugs in space on inflatable habitat’s first mission
An ADSEP with blue PIL-BOXs, hardware which will be delivered to Sierra Space for the LIFE habitat pathfinder mission. Redwire Space infrastructure company Redwire is putting a biotech technology testbed on Sierra Space’s first mission with its inflatable space habitat, establishing a new partnership between the two companies to make drugs in orbit. “It’s an […]
Read More